IXICO CEO discusses significance of two major neuroimaging contract wins

IXICO PLC (LSE:IXI, OTC:PHYOF) CEO Bram Goorden talked with Proactive's Stephen Gunnion about the company’s latest contract wins in two key therapeutic areas — Alzheimer’s disease and Friedreich’s Ataxia. Goorden said the first deal is a phase 1 international trial in Alzheimer’s disease with a major pharmaceutical company, reinforcing IXICO’s aim to deepen its involvement in this therapeutic area. “This is another testament to that happening as we speak,” he noted, adding that successful early-stage results could lead to further work in phase 2 and beyond.

The second contract is a phase 1b trial in Friedreich’s Ataxia, a rare neurodegenerative disease affecting about one in 50,000 people. IXICO will provide advanced imaging services, including MRI and DTI reads, over a six-year period for a US biotech client. Goorden emphasised that, despite its rarity, there is a “dire need for a solution” for patients, making this collaboration particularly meaningful.

Both deals align with IXICO’s 'innovate, lead, scale' strategy, demonstrating its capability to deliver sophisticated imaging solutions and maintain a presence in targeted disease ecosystems.

For more updates from IXICO PLC and other companies, visit Proactive’s YouTube channel, give this video a like, subscribe, and turn on notifications so you don’t miss future content.

#IXICOPLC #AlzheimersResearch #FriedreichsAtaxia #ClinicalTrials #NeurodegenerativeDiseases #CNSResearch #BiotechNews #MRIImaging #DrugDevelopment #RareDiseaseResearch